Kirkland Represents Clene Nanomedicine, Inc. on Merger with Tottenham Acquisition I Limited

Kirkland advised Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, on its business combination with Tottenham Acquisition I Limited (“Tottenham”) (NASDAQ: TOTA, TOTAU, TOTAW, TOTAR), a special purpose acquisition company. Clene is valued at approximately $542.5 million in the transaction and, upon the closing of the transactions, will be NASDAQ-listed under a new ticker symbol. Clene focuses on the development of potentially first-in-class nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases.

Read the press release from Clene Nanomedicine and Tottenham

The Kirkland team was led in Asia by capital markets partners David Zhang and Ben James and in the U.S. by transactional partner James Hu, and included tax partners Dean Shulman and Vivek Ratnam and executive compensation partner Michael Krasnovsky.